SynthesisCells2026
3D Bioprinting in Anterior Segment Ocular Tissue Engineering: Advances, Challenges, and Translational Pathways-A Systematic Review.
Synthesis in Cells, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Bioprinting has been proposed for nearly every structure of the anterior eye, but the effort is unevenly spent. We systematically reviewed 71 experimental studies of bioprinting across the anterior segment: cornea, conjunctiva, sclera, lens, lacrimal gland and eyelid. Most work targets the corneal stroma. The endothelium, the layer most often replaced surgically and the first to reach a clinical trial, accounts for the fewest preclinical studies. Beyond the cornea, printed constructs are mostly disease models rather than implants, and the iris, trabecular meshwork and ciliary body remain untouched. Preclinical testing remains short-term and confined to small animals. Studies measure the same properties in different ways, so constructs cannot be compared across laboratories. We map what has been printed for each tissue and how far each construct stands from the clinic, and propose a minimum reporting set to make the next generation of studies comparable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.